Comparing therapies for XXXX prevention and treatment.

@entity172 @entity1 @entity175 @entity171 @entity174 @entity561 @entity170 @entity79 @entity562 @entity460 @entity441 @entity560
OBJECTIVE: To review the literature concerning the efficacy of @entity460 , hormone replacement therapy (HRT), @entity171 , selective @entity172 receptor modulators, and @entity175 in the prevention and treatment of @entity170 . DATA SOURCES: Articles were identified through searches of the MEDLINE (1966-July 2002), EMBASE (1980-July 2002), and International Pharmaceutical Abstracts (1970-July 2002) databases using the key @entity170 , postmenopausal, @entity174 , @entity460 , @entity560 , hormone replacement therapy, @entity171 , @entity561 , @entity562 , @entity441 , and @entity175 . Additional references were located through review of the bibliographies of the articles cited. Searches were not limited by time restriction, language, or @entity1 subject. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational studies of the use of @entity460 and antiresorptive therapies for the prevention and treatment of @entity170 were selected. Articles evaluating @entity79 ( @entity79 ) or @entity174 efficacy were included in this review. DATA SYNTHESIS: HRT, @entity171 , @entity441 , and @entity175 have demonstrated stabilization of and improvement in @entity79 . Randomized clinical trials have shown @entity174 risk reduction with @entity171 , @entity441 , HRT, @entity460 , and @entity175 . The largest risk reductions have been reported with use of @entity171 in several trials. CONCLUSIONS: Several therapeutic options with well-documented improvements in @entity79 and reductions in @entity174 risk are available to @entity1 for the prevention and treatment of @entity170 .
